Connect with us

Business

A Region at a Turning Point

Published

on

A Region at a Turning Point

The Asian M&A landscape in 2025 painted a picture of cautious optimism layered over deep structural challenges. While regional deal values rose 10% and volumes increased a modest 3%, these aggregate figures mask a market experiencing profound fragmentation. 

The forces reshaping global dealmaking, artificial intelligence chief among them, are hitting Asia with particular intensity, exposing gaps in capital access, technological readiness, and strategic conviction across the region’s diverse economies.

Asia’s M&A recovery tells multiple stories simultaneously. China, after years of subdued activity, saw deal volumes surge 22% in 2025, though levels remain well below the 2021 peak. India, Japan, and South Korea all posted double-digit growth in deal values, signaling pockets of robust activity. Yet most other Asia Pacific markets reported year-over-year declines in deal volumes, revealing a region where momentum concentrates in select markets while others struggle to gain traction. 

This uneven performance reflects more than cyclical variation. It signals Asia’s positioning in a global M&A market increasingly defined by a K-shaped recovery, where scale, capital depth, and AI readiness separate winners from the rest.

Advertisement

The Capital Allocation Dilemma Hitting Asia Hard

Asian corporations face an acute version of the capital allocation challenge confronting dealmakers worldwide. External estimates suggest that between $5 trillion and $8 trillion will flow toward AI technologies and enabling infrastructure globally over the next five years. For context, global M&A activity totaled just $3.5 trillion in 2025. This multitrillion-dollar AI investment supercycle is forcing Asian companies to make stark choices between building AI capabilities and pursuing traditional growth-through-acquisition strategies.

The tension manifests differently across the region. Chinese technology companies, already investing heavily in AI development, find themselves navigating both technological transformation and geopolitical constraints that complicate cross-border dealmaking. Japanese conglomerates, sitting on substantial cash reserves, are weighing AI infrastructure investments against long-planned international acquisitions. Indian technology services firms are racing to acquire AI capabilities while defending market share against AI-enabled automation.

The immediate impact is visible in near-term M&A activity. Capital that might have funded acquisitions is instead flowing into data centers, semiconductor capacity, cloud infrastructure, and AI model development. This reallocation helps explain why Asia’s deal volume growth lags value growth, and why mid-market activity remains particularly subdued.

Geographic Confidence Gaps Shape Deal Activity

Perhaps no metric better illustrates Asia’s M&A fragmentation than CEO confidence levels. According to PwC’s Global CEO Survey, approximately 50% of Indian CEOs plan major acquisitions within the next three years, matching optimism levels in the United States. Yet only around 20% of Chinese CEOs express similar intent, placing China among the most cautious major markets globally alongside Germany. 

Advertisement

This confidence gap translates directly into dealmaking patterns. India’s M&A market benefits from strong domestic growth expectations, a robust technology sector, and increasing interest from both strategic acquirers and financial sponsors. The country’s position as a beneficiary of supply chain diversification and nearshoring trends further supports deal activity.

China’s more muted M&A sentiment reflects multiple headwinds: regulatory uncertainty, property sector challenges, geopolitical tensions affecting outbound investment, and questions about the sustainability of growth rates. While the 22% increase in deal volumes suggests improving conditions, Chinese companies remain more focused on domestic consolidation and strategic repositioning than aggressive expansion.

Japan occupies middle ground, with deal activity driven by demographic pressures, succession planning for family-owned businesses, and large corporations pursuing portfolio rationalization. South Korea’s double-digit value growth reflects both technology sector strength and industrial consolidation, particularly in sectors adjacent to semiconductors and advanced manufacturing.

AI’s Impact: From Manufacturing to Healthcare

Asia’s manufacturing-heavy economy means AI’s impact on M&A extends beyond pure technology deals. PwC’s analysis of the 100 largest global M&A transactions in 2025 found that approximately one-third cited AI as part of their strategic rationale, with technology, manufacturing, and power and utilities sectors showing the highest AI references. 

Advertisement

For Asian companies, this creates both pressure and opportunity. Traditional manufacturing firms are pursuing acquisitions to embed AI across operations, supply chains, and product development. Healthcare companies are acquiring data analytics and software capabilities to accelerate drug development and personalized medicine. Industrial conglomerates are buying robotics and automation assets to integrate AI-driven efficiency gains.

SoftBank’s proposed $5.4 billion acquisition of ABB’s robotics business exemplifies Asia’s strategic approach, positioning a major Japanese technology investor at the intersection of AI and industrial automation. The deal signals recognition that AI’s value emerges not from algorithms alone but from their integration into physical systems and real-world operations.

Chinese pharmaceutical companies are also active, with innovation in drug development driving strategic transactions despite broader market caution. These deals reflect China’s strategic priority on technological self-sufficiency and its determination to build domestic capabilities in sectors deemed critical for future competitiveness.

The Scale Disadvantage in a Megadeal World

Asia confronts a structural challenge in the current M&A environment: relative underrepresentation in megadeals. While the region generated solid mid-market activity, it captured a smaller share of transactions exceeding $5 billion compared to the Americas, which dominated megadeal activity in 2025.

Advertisement

This matters because megadeals drove the entire recovery in global M&A values. Roughly 600 transactions above $1 billion accounted for the 36% increase in global deal values, while the remaining 47,000 transactions were flat year-over-year. Asian companies and markets participating less actively in this megadeal wave risk being left behind as competitive dynamics increasingly favor scale.

Several factors explain Asia’s megadeal deficit. First, regulatory scrutiny of large transactions has intensified across multiple jurisdictions, particularly for deals touching sensitive technologies or critical infrastructure. Second, cross-border megadeals face heightened geopolitical risk, encouraging companies to pursue domestic or regional transactions rather than transformative global consolidation. Third, valuation gaps between Asian targets and global acquirers remain wide, complicating negotiations for the largest deals.

The exception proves the rule: where Asian companies do pursue megadeals, they increasingly focus on acquiring capabilities essential for AI competitiveness, particularly in semiconductors, data infrastructure, and advanced manufacturing.

Advertisement
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Former Iluka Resources boss Rob Cole to chair Committee for Perth

Published

on

Former Iluka Resources boss Rob Cole to chair Committee for Perth

Committee for Perth has appointed Perth Airport chair Rob Cole to succeed Tony Joyner as the head of the organisation.

Continue Reading

Business

Key approval attained for European Metals

Published

on

Key approval attained for European Metals

Shares in West Perth-based European Metals Holdings rose early on Tuesday morning on the back of the junior receiving a key approval for its flagship project.

Continue Reading

Business

Peninsula Energy Limited (PENMF) Presents at RRS Summer Series Sydney – Slideshow

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Peninsula Energy Limited (PENMF) Presents at RRS Summer Series Sydney – Slideshow

Continue Reading

Business

Smith Sculptors construct lasting legacy

Published

on

Smith Sculptors construct lasting legacy

Two artists are creating local works that withstand the test of time.

Continue Reading

Business

Caterpillar group president De Lange sells $16.3m in stock

Published

on


Caterpillar group president De Lange sells $16.3m in stock

Continue Reading

Business

Opinion: Navigating a changing world order

Published

on

Opinion: Navigating a changing world order

OPINION: Agility may be Australia’s most valuable strategic asset in a world drifting toward spheres of influence.

Continue Reading

Business

Amnish Aggarwal on stocks to watch amid market volatility

Published

on

Amnish Aggarwal on stocks to watch amid market volatility
The Indian markets have witnessed renewed investor interest across pharma, speciality chemicals, and exchange-traded services, with recent corporate earnings providing both optimism and caution. ET Now spoke with Amnish Aggarwal from Prabhudas Lilladher, who shared his insights on sector trends and specific stock preferences.

Pharma: Numbers Improving, Select Names Preferred

When asked about the pharma sector and potential investment preferences beyond CDMOs. Aggarwal noted, “Pharma in the past, say, if you look at last 10-15 days, it has been sort of coming back and the main reason was that the market was a lot jittery at that point of time and also the pharma valuations have been relative to the valuations at which they are quoting at. However, if you look at the numbers of the past few days, the numbers have been good. If you look at particularly the MNC pharma companies like GSK or Pfizer, the numbers are quite decent and the stocks are also not expensive. But having said that, our current preference still revolves around, say, names like Sun Pharma where the numbers are okayish and if you look at the overall scenario, the pharma as a pack continues to look good.”

Speciality Chemicals: Growth Potential with Patience
On speciality chemicals, Aggarwal emphasized a company-specific approach. “You see in speciality chemicals one has to look at from company to company. Navin Fluorine, particularly, the numbers have been pretty decent. But if you look at their future expansion plans and where the stock is currently poised, it is already trading at something like 37-38 times on FY28. But having said that, if the actual impact of this US trade deal plays out over a period of time, then there could be more growth opportunities for many of these chemical companies, but it is not something which is going to happen in a day. It will take its own sweet time.”

Advertisement

Currency and Operational Efficiencies
Addressing currency tailwinds and operational efficiency in pharma, Aggarwal remarked, “A currency tailwind first of all one has to look at that rupee used to be 88-89 and now whether it is going back to 89 I think I am particularly doubtful about it because it is definitely not likely to go there, it might not be 92 in the immediate term.”


“Now the second part is in many of these companies I would say there is a lot of gains from stable raw material prices as also the efficiency gains. So, to that extent the numbers of many of these pharma companies they seem sustainable. One has to separate between the generic pharma companies and the companies which are having more domestic exposure because in case of many of these generic pharma companies a couple of molecules which were actually driving the sales whether it is Zydus, whether it is I believe Dr Reddy’s and also those molecules they are not likely to get benefit from that, but definitely the numbers have been pretty decent for most of the names and the valuations are not expensive at this point of time,” he added.
Exchange Performance: BSE Margins and NSE Listing Impact
Regarding BSE’s recent performance, Aggarwal explained, “You see that if you look at BSE, then their profitability and margin they have improved over the quarters. But having said that the F&O segment is some bit, I would say, under pressure and the market is also not in that sort of a zone from the last, say, three months or so. So that is getting reflected in the performance of BSE because in exchanges it is highly, I would say, your operating leverage is very high which acts on both sides. So, last quarter the markets in general were very jittery. “Smallcap and midcaps were down quite a bit where BSE is also having, I would say, the bigger share because many of these older smallcap, midcaps they are listed only in BSE and also the overall sentiment actually plays out a role. So, it is just a passing phase and the things will rebound as we go along,” he added.

On the potential impact of the NSE IPO, Aggarwal added, “Difficult to say at this point of time, but if you look at global exchanges, so they actually get a valuation of 30 to 40 times very easily. So, is BSE overly expensive, that does not look at this point of time. But having said that, it will also be a function of how your NSE gets listed that is one and secondly in terms of volume you will also because once NSE gets listed, it will be listed only on BSE. So to that extent that, it will also be an advantage to BSE to some extent.”

EMS Sector: Divergence but Select Leaders Stand Out
Turning to EMS (Electronics Manufacturing Services), Aggarwal observed that numbers remain volatile. “The numbers on the EMS side, as you said, they have been very volatile because the companies have been either reporting very high numbers or where there are misses also, the misses have been very significant. Now, if you look at the Amber’s numbers yesterday, the numbers were quite good and if the summer season next time also remain strong as is expected for the air conditioners, I think the Amber as such should do well,” he said.

“Even in case of Dixon the numbers were pretty strong. So, Amber and Dixon which have been there listed from quite some time, where the numbers are strong and the valuations are not as expensive, they still seem to be better placed than some of the other companies,” he added.

Advertisement
Continue Reading

Business

WorkSafe targets 'widespread' WA abattoir safety issues

Published

on

WorkSafe targets 'widespread' WA abattoir safety issues

Some 562 improvement notices and six prohibition notices have been issued across 19 regional abattoirs around WA after WorkSafe conducted a ‘proactive’ inspection program.

Continue Reading

Business

India’s Lupin settles US patent dispute with Astellas Pharma for $90 million

Published

on

India’s Lupin settles US patent dispute with Astellas Pharma for $90 million


India’s Lupin settles US patent dispute with Astellas Pharma for $90 million

Continue Reading

Business

CrowdStrike After The Correction: Same Story, Far Cheaper

Published

on

CrowdStrike After The Correction: Same Story, Far Cheaper

CrowdStrike After The Correction: Same Story, Far Cheaper

Continue Reading

Trending

Copyright © 2025